Mon Dec 16 06:30:51 UTC 2024: ## Hamps Bio IPO Oversubscribed by 8.79 Times

**Mumbai, December 13** – The initial public offering (IPO) of Hamps Bio, a pharmaceutical and FMCG company, saw an overwhelmingly positive response on its launch day, closing with an overall subscription rate of 8.79 times by 4:00 p.m. Retail investors showed particularly strong interest, oversubscribing their portion by a significant 15.83 times. While the non-institutional investor (NII) segment subscribed 1.75 times, no allocation was made for qualified institutional buyers (QIBs).

Hamps Bio, which manufactures and markets a wide range of pharmaceutical formulations and FMCG products including tablets, syrups, and nutrition supplements, plans to use the IPO proceeds to upgrade its plant and machinery, boost brand visibility, and cover general corporate expenses. The company distributes its products through over 50 distributors and major e-commerce platforms like Amazon and Flipkart.

Market sources suggest a grey market premium (GMP) of ₹21, indicating a potential listing price of ₹72, compared to the issue price of ₹51.

The IPO is managed by Marwadi Chandarana Intermediaries Brokers Pvt. Ltd., with Bigshare Services Pvt. Ltd. acting as registrar and Pure Broking as the market maker. While the strong retail investor response signals high demand, potential investors are advised to seek guidance from certified financial advisors before making investment decisions.

Read More